BiRDS Pharma GmbH is actively seeking investors to push its own drug development projects to a later stage that allows for partnering with the pharmaceutical industry. To investors who are interested to invest in one or more of BiRDS Pharma GmbH's drug development projects, two investment models based on shareholding are proposed: Investment could either be directly into BiRDS Pharma GmbH or alternatively into one or more affiliate project companies, that provide financing vehicles for individual projects. Whereas investment into BiRDS Pharma GmbH offers to investors the advantage to participate to the whole value creation by the company and at the same time reduces risk of investment due to the balanced project portfolio, specific investment into one project company offers the advantage of a focussed investment into on specific preferred project. According to the preferences of investors, project companies can be founded for BiRDS Pharma GmbH's projects based on AST. Each investment from financial investors (or development partners) will typically be based on shareholding to avoid conflicts of interest and to assure returns based on contribution. Here, for example, an investment into BiRDS Pharma GmbH will at the same time lead to shareholding in the project companies according to the contributions of BiRDS Pharma GmbH to the development of each respective project. Alternatively, investments into individual projects will be translated into shares in the project companies. Returns to investors and development partners are expected from partnering or sale of the projects or by an initial public offering (IPO) of BiRDS Pharma GmbH or one or more of the project companies.